This segment focuses on the development, manufacturing, and marketing of blood glucose monitoring systems and related products. Sinocare's R&D efforts are directed towards improving the accuracy, reliability, and user-friendliness of its glucose meters. Technologies employed include biosensor technology and electrochemical detection methods. The segment addresses the needs of patients with diabetes, providing tools for self-monitoring and glycemic control. Sinocare aims to enhance patient outcomes by offering affordable and accessible diabetes management solutions, particularly in emerging markets. The company's market positioning is strengthened by its focus on innovation and strategic partnerships. Future opportunities include expanding the product line to include continuous glucose monitoring (CGM) systems and integrated diabetes management platforms. Regulatory compliance and clinical validation are critical aspects of this segment.

Sinocare's POCT segment involves the development and distribution of rapid diagnostic tests for various health conditions. This includes tests for blood glucose, uric acid, and other biomarkers. R&D activities focus on creating accurate and easy-to-use testing devices suitable for use in primary care settings and at home. Technologies used include lateral flow assays and microfluidics. The segment aims to improve access to healthcare by providing timely diagnostic information at the point of care, enabling faster clinical decision-making. Sinocare's competitive advantage lies in its ability to offer cost-effective POCT solutions, particularly in developing countries. Future growth potential includes expanding the range of tests offered and integrating POCT devices with digital health platforms. Regulatory approvals and quality control are essential for maintaining the integrity of this segment.